Proteinuria among patients with chronic kidney disease: A performance measure for improving patient outcomes

Micah L. Thorp, David H. Smith, Eric S. Johnson, Suma Vupputuri, Jessica Weiss, Amanda F. Petrik, Xuihai Yang, Andrew S. Levey, Haimanot Wasse, Rosemary Muoneke, Susan R. Snyder

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: In an effort to improve identification and treatment of patients with chronic kidney disease (CKD), the National Kidney Foundation (NKF) developed the Kidney Disease Quality Outcomes Initiative (KDQOI) clinical practice guidelines, which include measurement of proteinuria among all patients with CKD who are not receiving chronic dialysis therapy. Encouraging dissemination and utilization of these guidelines may be enhanced by the development of performance measures. The question of whether adequate evidence exists to advocate for the measurement of proteinuria in CKD as a performance measure was explored. Methods: The US Preventive Services Task Force "chain of evidence" framework was used to guide evidence synthesis from the systematic review. Five questions were applied to specific links in the evidence chain: (1) Is there direct evidence that testing for proteinuria improves health outcomes? (2) What is the yield of testing, in terms of both accuracy and reliability of the test and the prevalence of undiagnosed proteinuria? (3) What adverse effects result from testing a person for proteinuria? (4) Does treatment of proteinuria as a result of testing provide an incremental benefit in health outcomes? and (5) What adverse effects result from treating a person for proteinuria? The systematic search specifically targeted meta-analyses and systematic reviews. Findings: The systematic review revealed no direct evidence that testing for proteinuria among patients with CKD reduced incidence of end-stage renal disease (ESRD). However, the strong links between testing, treatment, and outcome suggest a correlation between proteinuria testing and ESRD. Conclusions: Current evidence suggests that proteinuria testing (using the albumin-to-creatinine ratio [ACR]) among patients with CKD would be an appropriate health care quality performance measure for improving patient outcomes. Copyright 2012

Original languageEnglish (US)
Pages (from-to)277-282
Number of pages6
JournalJoint Commission Journal on Quality and Patient Safety
Volume38
Issue number6
StatePublished - Jun 2012

Fingerprint

Chronic Renal Insufficiency
Proteinuria
Chronic Kidney Failure
Quality of Health Care
Kidney Diseases
Insurance Benefits
Advisory Committees
Practice Guidelines
Meta-Analysis
Dialysis
Albumins
Creatinine
Therapeutics
Guidelines
Kidney
Incidence
Health

ASJC Scopus subject areas

  • Leadership and Management

Cite this

Thorp, M. L., Smith, D. H., Johnson, E. S., Vupputuri, S., Weiss, J., Petrik, A. F., ... Snyder, S. R. (2012). Proteinuria among patients with chronic kidney disease: A performance measure for improving patient outcomes. Joint Commission Journal on Quality and Patient Safety, 38(6), 277-282.

Proteinuria among patients with chronic kidney disease : A performance measure for improving patient outcomes. / Thorp, Micah L.; Smith, David H.; Johnson, Eric S.; Vupputuri, Suma; Weiss, Jessica; Petrik, Amanda F.; Yang, Xuihai; Levey, Andrew S.; Wasse, Haimanot; Muoneke, Rosemary; Snyder, Susan R.

In: Joint Commission Journal on Quality and Patient Safety, Vol. 38, No. 6, 06.2012, p. 277-282.

Research output: Contribution to journalArticle

Thorp, ML, Smith, DH, Johnson, ES, Vupputuri, S, Weiss, J, Petrik, AF, Yang, X, Levey, AS, Wasse, H, Muoneke, R & Snyder, SR 2012, 'Proteinuria among patients with chronic kidney disease: A performance measure for improving patient outcomes', Joint Commission Journal on Quality and Patient Safety, vol. 38, no. 6, pp. 277-282.
Thorp, Micah L. ; Smith, David H. ; Johnson, Eric S. ; Vupputuri, Suma ; Weiss, Jessica ; Petrik, Amanda F. ; Yang, Xuihai ; Levey, Andrew S. ; Wasse, Haimanot ; Muoneke, Rosemary ; Snyder, Susan R. / Proteinuria among patients with chronic kidney disease : A performance measure for improving patient outcomes. In: Joint Commission Journal on Quality and Patient Safety. 2012 ; Vol. 38, No. 6. pp. 277-282.
@article{b7dcad227f534c67af5426e87da3f73e,
title = "Proteinuria among patients with chronic kidney disease: A performance measure for improving patient outcomes",
abstract = "Background: In an effort to improve identification and treatment of patients with chronic kidney disease (CKD), the National Kidney Foundation (NKF) developed the Kidney Disease Quality Outcomes Initiative (KDQOI) clinical practice guidelines, which include measurement of proteinuria among all patients with CKD who are not receiving chronic dialysis therapy. Encouraging dissemination and utilization of these guidelines may be enhanced by the development of performance measures. The question of whether adequate evidence exists to advocate for the measurement of proteinuria in CKD as a performance measure was explored. Methods: The US Preventive Services Task Force {"}chain of evidence{"} framework was used to guide evidence synthesis from the systematic review. Five questions were applied to specific links in the evidence chain: (1) Is there direct evidence that testing for proteinuria improves health outcomes? (2) What is the yield of testing, in terms of both accuracy and reliability of the test and the prevalence of undiagnosed proteinuria? (3) What adverse effects result from testing a person for proteinuria? (4) Does treatment of proteinuria as a result of testing provide an incremental benefit in health outcomes? and (5) What adverse effects result from treating a person for proteinuria? The systematic search specifically targeted meta-analyses and systematic reviews. Findings: The systematic review revealed no direct evidence that testing for proteinuria among patients with CKD reduced incidence of end-stage renal disease (ESRD). However, the strong links between testing, treatment, and outcome suggest a correlation between proteinuria testing and ESRD. Conclusions: Current evidence suggests that proteinuria testing (using the albumin-to-creatinine ratio [ACR]) among patients with CKD would be an appropriate health care quality performance measure for improving patient outcomes. Copyright 2012",
author = "Thorp, {Micah L.} and Smith, {David H.} and Johnson, {Eric S.} and Suma Vupputuri and Jessica Weiss and Petrik, {Amanda F.} and Xuihai Yang and Levey, {Andrew S.} and Haimanot Wasse and Rosemary Muoneke and Snyder, {Susan R.}",
year = "2012",
month = "6",
language = "English (US)",
volume = "38",
pages = "277--282",
journal = "Joint Commission Journal on Quality and Patient Safety",
issn = "1553-7250",
publisher = "Joint Commission Resources, Inc.",
number = "6",

}

TY - JOUR

T1 - Proteinuria among patients with chronic kidney disease

T2 - A performance measure for improving patient outcomes

AU - Thorp, Micah L.

AU - Smith, David H.

AU - Johnson, Eric S.

AU - Vupputuri, Suma

AU - Weiss, Jessica

AU - Petrik, Amanda F.

AU - Yang, Xuihai

AU - Levey, Andrew S.

AU - Wasse, Haimanot

AU - Muoneke, Rosemary

AU - Snyder, Susan R.

PY - 2012/6

Y1 - 2012/6

N2 - Background: In an effort to improve identification and treatment of patients with chronic kidney disease (CKD), the National Kidney Foundation (NKF) developed the Kidney Disease Quality Outcomes Initiative (KDQOI) clinical practice guidelines, which include measurement of proteinuria among all patients with CKD who are not receiving chronic dialysis therapy. Encouraging dissemination and utilization of these guidelines may be enhanced by the development of performance measures. The question of whether adequate evidence exists to advocate for the measurement of proteinuria in CKD as a performance measure was explored. Methods: The US Preventive Services Task Force "chain of evidence" framework was used to guide evidence synthesis from the systematic review. Five questions were applied to specific links in the evidence chain: (1) Is there direct evidence that testing for proteinuria improves health outcomes? (2) What is the yield of testing, in terms of both accuracy and reliability of the test and the prevalence of undiagnosed proteinuria? (3) What adverse effects result from testing a person for proteinuria? (4) Does treatment of proteinuria as a result of testing provide an incremental benefit in health outcomes? and (5) What adverse effects result from treating a person for proteinuria? The systematic search specifically targeted meta-analyses and systematic reviews. Findings: The systematic review revealed no direct evidence that testing for proteinuria among patients with CKD reduced incidence of end-stage renal disease (ESRD). However, the strong links between testing, treatment, and outcome suggest a correlation between proteinuria testing and ESRD. Conclusions: Current evidence suggests that proteinuria testing (using the albumin-to-creatinine ratio [ACR]) among patients with CKD would be an appropriate health care quality performance measure for improving patient outcomes. Copyright 2012

AB - Background: In an effort to improve identification and treatment of patients with chronic kidney disease (CKD), the National Kidney Foundation (NKF) developed the Kidney Disease Quality Outcomes Initiative (KDQOI) clinical practice guidelines, which include measurement of proteinuria among all patients with CKD who are not receiving chronic dialysis therapy. Encouraging dissemination and utilization of these guidelines may be enhanced by the development of performance measures. The question of whether adequate evidence exists to advocate for the measurement of proteinuria in CKD as a performance measure was explored. Methods: The US Preventive Services Task Force "chain of evidence" framework was used to guide evidence synthesis from the systematic review. Five questions were applied to specific links in the evidence chain: (1) Is there direct evidence that testing for proteinuria improves health outcomes? (2) What is the yield of testing, in terms of both accuracy and reliability of the test and the prevalence of undiagnosed proteinuria? (3) What adverse effects result from testing a person for proteinuria? (4) Does treatment of proteinuria as a result of testing provide an incremental benefit in health outcomes? and (5) What adverse effects result from treating a person for proteinuria? The systematic search specifically targeted meta-analyses and systematic reviews. Findings: The systematic review revealed no direct evidence that testing for proteinuria among patients with CKD reduced incidence of end-stage renal disease (ESRD). However, the strong links between testing, treatment, and outcome suggest a correlation between proteinuria testing and ESRD. Conclusions: Current evidence suggests that proteinuria testing (using the albumin-to-creatinine ratio [ACR]) among patients with CKD would be an appropriate health care quality performance measure for improving patient outcomes. Copyright 2012

UR - http://www.scopus.com/inward/record.url?scp=84862192599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862192599&partnerID=8YFLogxK

M3 - Article

C2 - 22737779

AN - SCOPUS:84862192599

VL - 38

SP - 277

EP - 282

JO - Joint Commission Journal on Quality and Patient Safety

JF - Joint Commission Journal on Quality and Patient Safety

SN - 1553-7250

IS - 6

ER -